The number one aim of this year's Tumour Model London meeting is to improve the predictability and translatability of preclinical oncology research.

1. Harness Clinically Relevant Cancer Models
Improve Predictability & Translatability of Research
Smartly Interpret to Ensure Clinical Trial Efficacy
EXPERT SPEAKERS INCLUDE:
Anderson Ryan
Senior Group Leader in
Radiation Oncology
University of Oxford
Sabine Hoves
Senior Scientist, Discovery
Oncology
Roche
Edward Rosfjord
Principal Research Scientist
Pfizer
Manuel Hidalgo
Vice Director of Translational
Research, Clinical Research
Programme Director
Spanish National Cancer
Research Centre (CIOCC)
Rajendra Kumari
CSO
PRECOS Ltd, A Crown
Bioscience Company
Neal Goodwin
VP Corporate Research &
Development
Champions Oncology
LEAD PARTNER:
Nicola McCarthy
Oncology Program
Manager
Horizon Discovery
Barry Davies
Principal Scientist
AstraZeneca
Hazel Jones
Head of Combination
Therapies, Drug
Development Office
Cancer Research UK
Tel: +44 (0)203 141 8700 | Email: info@hansonwade.com RESEARCHED & DEVELOPED BY:
www.tumour-models.com
PROGRAMME PARTNER: SPOTLIGHT PARTNER:
Tumour Models London
2nd-4th December 2014
2nd-4th December 2014 | London

2. Tumour Models London
2nd-4th December 2014
Tel: +44 (0)203 141 8700 Email: info@hansonwade.com
tumour-models.com Tumour Models
1 6
3 8
2 7
4 9
5 10
BENEFITS OF ATTENDING
Increase Clinical Trial Success Rates
With Predictive Tumour Models
Fail Smartly and Learn Fast: Harness Physiologically Relevant Tumour Models to
Optimise Translational Research into Clinical Value
With the Tumour Models Community gathering real
momentum in 2014 after the 3rd Tumor Models Boston
Summit, join the 4th Tumour Models Summit in London
to gain unpublished data from case studies, where you will
discover how clinically relevant tumour models are being
applied to better predict drug efficacy action within patient
subgroups.
You will benefit from an in-depth focus on cutting edge in
vivo and in vitro modelling best practice, and discover the
movement towards more physiologically relevant models
that better mimic the tumour environment, represent the
patient population and help you prioritise drug candidates.
This is the opportunity for you to collaborate with other
preclinical oncologists and translational researchers to uncover
novel emerging models and effective preclinical strategies to
only advance your most promising candidates.
Exchange knowledge to improve the interpretation of your data
derived from tumour model studies and reduce failure rates of
oncology clinical trials.
Leave inspired with new ideas, tools and connections to
maximise the potential of your discoveries.
Discover the latest developments for clinically
relevant tumour models in preclinical trials to
enhance your drug development
Harness in vitro modelling to investigate
mechanisms of drug resistance that better
represent response to therapy
TOP 10 REASONS TO ATTEND TUMOUR MODELS LONDON 2014:
Learn about the most innovative immuno-competent
in vitro and in vivo models
being used in the development of cancer-immunotherapies
Explore how establishing a preclinical model
network can enhance the development of
combination therapies
Harness PDX models to improve the
representation of the patient population and
enhance translational decision making
Discover the technological advancements in
the field of preclinical tumour modelling and
improve your preclinical predictions
Discover the emergence of 3D modelling in
drug candidate development to specifically
target the tumour microenvironment
Learn how applying next generation
sequencing can improve the development of
personalised cancer therapies
Explore the advanced pharmaco-imaging
technology being used to monitor the
pharmacokinetics in tumour models and
improve drug efficacy
Understand the importance of enhancing
translational collaborations to improve
drug discovery, efficacy testing and overall
translational success

3. SPEAKER FACULTY
Tumour Models London
2nd-4th December 2014
Tel: +44 (0)203 141 8700 Email: info@hansonwade.com
tumour-models.com Tumour Models
Neal Goodwin
VP Corporate Research &
Development
Champions Oncology
William Shingler
Development Project Manager
Immunocore
Stefanie Mullins
Scientist I
MedImmune
Nicola McCarthy
Oncology Program Manager
Horizon Discovery
Anderson Ryan,
Senior Group Leader in
Radiation Oncology
University of Oxford
Barry Davies
Principal Scientist
AstraZeneca
Frances Richards
Pharmacology & Drug
Development Group Lab Head
Cancer Research UK
Cambridge Institute
Els Hermans
Research Manager PDTX
Platform
University Hospital Leuven
Sue Eccles
Professor of Experimental
Cancer Therapeutics
Institute of Cancer Research
Edward Rosfjord
Principal Research Scientist
Pfizer
Louise Jones
Professor of Breast Pathology
Barts Cancer Institute
Aaron Cranston
Head of in vivo Pharmacology
MISSION Therapeutics
Thomas Pöschinger
Preclinical Imaging Scientist,
Discovery Oncology, pRED
Roche
Sabine Hoves
Senior Scientist, Discovery
Oncology
Roche
Hazel Jones
Head of Combination
Therapies, Drug Development
Office
Cancer Research UK
Outstanding meeting with first class
speakers. I learned a lot and I will
certainly recommend the meeting to my
colleagues Sanofi Aventis
Manuel Hidalgo
Vice Director of Translational
Research, Clinical Research
Programme Director
Spanish National Cancer
Research Centre (CIOCC)
Rajendra Kumari
CSO
PRECOS Ltd, A Crown Bioscience
Company

4. Tumour Models London
2nd-4th December 2014
Tel: +44 (0)203 141 8700 Email: info@hansonwade.com
tumour-models.com Tumour Models
WORKSHOP A
WORKSHOP B
Through this interactive peer to peer session you will learn:
• How to generate and characterise preclinical models for the development of combination
therapies
• What are the current advantages and limitations of the preclinical models used in the
discovery of combination therapies
• How to identify and implement these models to enhance preclinical predictions
• The application of GEMM models within combination therapy development
From this in-depth session you will take away:
• The main advantages of PDX models over standard Xenograft models in optimising translational
decision making
• Application of xenograft models to predict patient response and prioritise which candidates to progress in phase II
patient studies
• How to harness and refine PDX models for proof of confidence studies and enhance predictability of preclinical
studies
• How to use PDX models to overcome dosage selection and toxicology challenges, in order to enhance the
translational outcomes
• How the use of PDX models in preclinical research using can improve clinical trial design
Dr Hazel Jones is head of combination therapies Cancer Research UK.
Hazel has extensive experience in developing preclinical models and is currently
collaborating with leading UK researchers to discuss how to make models more accessible
for translational research across the UK.
Workshop leader
Hazel Jones
Head of Combination Therapies,
Drug Development Office
Cancer Research UK
Establishing a Network of Preclinical Models to Enhance the
Development of Combination Therapies
Date: Tuesday 2nd December 2014 | Time: 9.00am – 12.00pm
Developing and Harnessing Patient Derived Xenograft (PDX)
Models to Better Demonstrate Drug Efficacy Action and
Improve Translational Decision Making
Date: Tuesday 2nd December 2014 | Time: 1.00pm – 4.00pm
Workshop leader
Barry Davies
Principal Scientist
AstraZeneca
Dr Barry Davies is a Principal Scientist in Oncology Innovative Medicines at AstraZeneca.
Barry has expertise in cancer cell biology, and wide experience of drug discovery and early development from target selection to Phase 2
proof of concept studies.

5. Tumour Models London
2nd-4th December 2014
Tel: +44 (0)203 141 8700 Email: info@hansonwade.com
tumour-models.com Tumour Models
8.00 Registration & Breakfast
9.00 Chairman’s Opening Remarks
Model into Human: The Preclinical Holy Grail
9.10 Conversations That Matter: Developing and Utilising a
Selection of Truly Predictive Models
Eavesdrop on exclusive one-to-one interviews with key opinion
leaders, who are leading the way to improve the predictability
and translational success of preclinical oncology research:
• What are the current limitations in clinically-relevant
preclinical models?
• Is the industry seeing any clinical success stories using novel
models?
• Are we designing the right models and using these models to
ask the right questions?
Edward Rosfjord, Principal Research Scientist, Pfizer
Anderson Ryan, Senior Group Leader in Radiation Oncology
University of Oxford
Modelling for Immunotherapeutic Drug Discovery
10.00 De-Risking Late Stage Development: Optimising Translational
Research for Clinical Value
• Human surrogate clinical trials: Utilising large portfolios of
models to accurately represent patient population
• Enhanced in vivo models for the development of immune-therapeutics
Rajendra Kumari, CSO, PRECOS Ltd, A Crown Bioscience
Company
10.30 Speed Networking & Morning Refreshments
11.30 Syngeneic Mouse Models in Onco-Immunology and How They
Translate into Clinical Trials
• Relevance of syngeneic mouse models for prediction
of changes in the tumour infiltrate after treatment with
immunotherapies
• Analysing the myeloid immune cell infiltrate in syngeneic
tumour models
Sabine Hoves, Senior Scientist, Discovery Oncology, Roche
12.00 Development of T Cell Receptor-Based Biologics: An in vitro
Route to the Clinic
• Clinical experience: How predictive was the IMCgp100 in vitro
toxicity and efficacy package?
• Enhancing ImmTAC preclinical specificity testing: A lesson
learned
William Shingler, Development Project Manager, Immunocore
A Movement Towards Physiologically Relevant Models
12.30 Definitive and Controlled Preclinical Model Systems Through
the Use of Isogenic Cell Lines
• Combining knowledge of tumour biology and
microenvironment with cell lines to predict drug action
Nicola McCarthy, Oncology Program Manager, Horizon
Discovery
12.45 Networking Lunch
2.00 Models for Targeted Therapies for Disseminated Disease
• Challenges of target validation and drug development in
invasion and metastasis: 3D in vitro functional assays
• Getting the most out of human tumour xenografts
Sue Eccles, Professor of Experimental Cancer Therapeutics,
Institute of Cancer Research
2.30 Multicellular 3D in vitro Models to Study Disease Progression
and the Impact of the Microenvironment
• Generating appropriate cell populations to study normal, pre-malignant
and malignant disease
• Capturing the heterogeneity of cancer
Louise Jones, Professor of Breast Pathology, Barts Cancer
Institute
Personalised & Heterogeneous Models for Enhanced Drug
Efficacy
3.00 Patient Specific and Clinically Relevant PDX Programme for
Clinical Advancement
• Application of PDX models to improve preclinical predictions
and optimise translational decision making
Neal Goodwin, VP Corporate Research & Development,
Champions Oncology
3.30 Afternoon Refreshments
4.00 Preclinical Tumour Models: Their Role in our Mission from
Drug Discovery to Clinical Practice
• How do we and how should we interpret the data?
• Planning for success: The path from bench to bedside (and
the models in between)
Aaron Cranston, Head of in vivo Pharmacology, MISSION
Therapeutics Ltd
4.30 Tumour Model Breakout Roundtables
The Tumour Models speaker faculty is second to none, but there
is just as much knowledge in the audience as there is onstage.
Tap into your peers’ wealth of expertise on key issues during
Breakout Roundtables:
1. How do we validate PDTX models for histologic and genetic
profiling?
2. Do current models address the key issues, and what about
animal ethics?
3. How to implement the most accurate in vitro models to
compliment in vivo studies
4. How to use the combination of NGS and tumour modelling to
better represent the patient population
5. How to optimise PDX models to predict efficacy of ADCs
Els Hermans, Research Manager PDTX Platform, University
Hospital Leuven
Sue Eccles, Professor of Experimental Cancer Therapeutics,
Institute of Cancer Research
5.30 Chair’s Closing Remarks
5.40 Close of Day 1
CONFERENCE DAY 1 - Wednesday 3rd December 2014
Keynote Session Interactive Session Networking Session

6. Tumour Models London
2nd-4th December 2014
Tel: +44 (0)203 141 8700 Email: info@hansonwade.com
tumour-models.com Tumour Models
8.00 Breakfast
9.00 Chairman’s Opening Remarks
Translatability: Interpreting Data into the Clinic
9.10 Reverse Translation: Using Preclinical Studies to Better
Understand Emerging Clinical Data
• Understanding how preclinical studies are crucial in guiding
patient and biomarker selection strategies and clinical
developments
• How preclinical studies are critical to our understanding of
emerging clinical data
• Their importance in redefining clinical plans as more
opportunities in new disease settings are discovered
Anderson Ryan, Senior Group Leader in Radiation Oncology
University of Oxford
9.40 Integrating NGS and Avatar Mouse Models in Personalised
Cancer Treatment
• How avatar models have been utilised in personalised
medicine programmes and crucially what are the main
advantages and limitations of this approach
Manuel Hidalgo, Vice Director of Translational Research,
Clinical Research Programme Director, Spanish National
Cancer Research Centre (CIOCC)
10.10 Enhancing Both in vitro and in vivo Modelling for the
Development of Combination Immunotherapies
• To discuss the use of in vitro models in the development of
small molecular inhibitors
• How the combination of different in vivo models can enhance
the discovery of new immunotherapies
Stefanie Mullins, Scientist I, MedImmune
10.40 Morning Refreshments
11.10 Application of Non-Invasive Imaging Technologies to Monitor
Pharmacodynamic Effects in Orthotopic Cancer Models
• Applying bioluminescence and fluorescence imaging
• Micro-computed tomography and the combination thereof
in several orthotopic tumour models, e.g. brain, breast, and
lung cancer
Thomas Pöschinger, Preclinical Imaging Scientist, Discovery
Oncology, pRED, Roche
11.40 Application of Xenograft Models to Predict Patient Response
and Prioritise Schedule of the AKT Inhibitor AZD5363 in
Patients
• How to use a predictive PK-PD-efficacy modelling approach
in xenografts to compare the relative efficacy of three
different schedules of AZD5363
• How has this been applied to prioritise which schedule to take
forward into phase II in patients
Barry Davies, Principal Scientist, AstraZeneca
12.10 Understanding the Importance and Application of PDX Models
to Improve Preclinical Predictions and Optimise Translational
Decision Making
• How PDX models can optimise biomarker identification and
validation
• How PDX models can better represent tumour heterogeneity
present with the patient population
Edward Rosfjord, Principal Research Scientist, Pfizer
12.40 Networking Lunch
Overcoming Resistance Mechanisms & Modelling for
Combination Therapies
2.00 An in vitro Co-Culture Model of Pancreatic Cancer for
Investigation of Drug Resistance and Efficacy
• Description of the development of an in vitro co-culture model
of pancreatic ductal adenocarcinoma
• Identification of chemo-resistance in the model
Frances Richards, Pharmacology & Drug Development Group
Lab Head, Cancer Research UK Cambridge Institute
2.30 Harnessing a Preclinical Model Network for Effective
Combination Therapy Screening
• Modelling to test efficacy for combination therapies
• Predicting the impact of combination therapies on the tumour
Hazel Jones, Head of Combination Therapies, Drug
Development Office, Cancer Research UK
Enhancing Translational Collaborations
3.00 Interactive Solution Finding Session: How to Enhance Both
Internal and External Collaborations to Enhance Drug
Discovery, Efficacy Testing and Translational Success
Tumour models are only as good as the data derived from them
and how it is interpreted to influence translational and clinical
decisions. This session will discuss and debate how:
• Communication can be improved between preclinical and
clinical teams
• To ensure preclinical data positively impacts translational
decisions and clinical trial design
• Public private partnerships are leveraging external expertise
3.30 Afternoon Refreshments
4.00 Roundtable Intelligence & Mastermind Discussion
Missed a roundtable you wished you were at or have
unanswered questions to your specific challenges? Fear not as
roundtable moderators summarise the key industry intelligence
from the earlier discussions, providing you one final opportunity
to outline key future trends for the field
• How can the field reinvigorate the negative mind-set facing
cancer drug development to overhaul high clinical attrition
rates?
• What are the future trends for cancer drug discovery and
efficacy testing?
• How can we, as the Tumour Models community, implement
key solutions to affect positive change and foster innovation?
4.30 Chair’s Closing Remarks
4.40 Close of Congress
CONFERENCE DAY 2 - Thursday 4th December 2014
Keynote Session Interactive Session Networking Session

7. Tumour Models London
2nd-4th December 2014
Tel: +44 (0)203 141 8700 Email: info@hansonwade.com
tumour-models.com Tumour Models
SPONSORS
JOIN THE TUMOUR MODEL COMMUNITY:
Contact
Diane McKenna
Commercial Director, Tumour Models
Tel: +44 (0)203 141 8700
Email: sponsor@hansonwade.com
Lead Partner – Crown Bioscience
Crown Bioscience provides Translational Platforms focused
on fast-tracking candidates to identify biomarkers and patient
responders based on the pharmacological response of human
surrogate models. Power your Drug Discovery using the world’s
largest commercial collection of well-characterised PDX in
passage (HuPrime) plus a curated, searchable database of
patient, genotypic and phenotypic data as well as pharmacological
response (HuBase). Identify potential biomarkers (HuSignature™)
based on pharmacological response or use your biomarker
signature to identify models available for screening to confirm
patient responder and non-responder populations (HuTrials™).
Fast forward your discovery programmes today.
www.crownbio.com
Programme Partner – Champions Oncology
Champions Oncology was founded by renowned specialists
in the field of cancer diagnosis, treatment, and research. The
Champions Oncology team is comprised of seasoned oncology
professionals passionately dedicated to working to accelerate
oncology drug development, improve treatment outcomes and
extend lives. Our core platform, the Champions TumorGraft™
offers an enhanced xenograft mouse avatar model for growing
and testing human tumours. Champions Personalized
TumorGrafts™ empower patients and physicians using an in
vivo xenograft mouse avatar based diagnostic model that has
shown to be predictive of a patients’ clinical response to cancer
treatments and anticancer therapies.
www.championsoncology.com
Tumour Models London is proud to partner with:
LEAD PARTNER PROGRAMME PARTNER
Spotlight Partner – Horizon Discovery
Horizon Discovery combines long scientific heritage in
translational research with GENESIS™, a precision gene editing
platform incorporating rAAV, CRISPR and ZFN technologies.
Horizon supplies genetically-defined cell lines, gene-editing tools
and services, custom cell line generation, molecular reference
standards, and contract research services to approaching 1,000
academic, clinical and biopharmaceutical organisations.
www.horizondiscovery.com
SPOTLIGHT PARTNER
A very enjoyable meeting. Very
interesting to hear how other
companies are using in vivo models
and their thought processes.
Sanofi

8. Code: 4531
* All discount offers (including team discounts) require payment at the time of registration to receive any discount. ‘Early Bird’ discounts require
payment at time of registration and on or before the cut-off date to receive any discount. All discount offers cannot be combined with any other offer.
The conference fee includes lunch, refreshments and course documentation. The fee does not include travel or hotel accommodation.
Full payment is due on registration. Cancellation and Substitution
Policy: Cancellations must be received in writing. If the cancellation
is received more than 14 days before the conference attendees will
receive a full credit to a future conference. Cancellations received
14 days or less (including the fourteenth day) prior to the conference
will be liable for the full fee. A substitution from the same
organisation can be made at any time.
Changes to Conference & Agenda: Hanson Wade reserves the right
to postpone or cancel an event, to change the location or alter the
advertised speakers. Hanson Wade is not responsible for any loss
or damage or costs incurred as a result of substitution, alteration,
postponement or cancellation of an event for any reason and
including causes beyond its control including without limitation, acts
of God, natural disasters, sabotage, accident, trade or industrial
disputes, terrorism or hostilities.
Data Protection: The personal information shown and/or provided by
you will be held in a database. It may be used to keep you up to date
with developments in your industry. Sometimes your details may be
obtained or made available to third parties for marketing purposes.
If you do not wish your details to be used for this purpose, please
write to: Database Manager, Hanson Wade, 4th Floor, 52 Grosvenor
Gardens, London, SW1W 0AU
Hanson Wade Limited. Registered in England & Wales. Company
No: 6752216
TERMS & CONDITIONS
VENUE AND ACCOMMODATION:
REGISTER EVENT PRICES
PRICING & VENUE
STANDARD PRICES
PACKAGE
Register &
Pay before
22nd August
Register & Pay
before 26th
September
Register & Pay
before 31st October Standard Price
CONFERENCE + 2
WORKSHOPS
£2197 +VAT
(save £800)
£2397 +VAT
( save £600)
£2597 +VAT
(save £400)
£2797 +VAT
(save £200)
CONFERENCE + 1
WORKSHOP
£1698 +VAT
(save £700)
£1898 +VAT
(save £500)
£2098 +VAT
(save £300)
£2298 +VAT
(save £100)
CONFERENCE ONLY £1199 +VAT
(save £600)
£1399 +VAT
(save 400)
£1599 +VAT
(save £200) £1799 +VAT
HALF DAY
WORKSHOP £599 +VAT
ACADEMIC / NOT FOR PROFIT PRICES
PACKAGE
Register &
Pay before
22nd August
Register & Pay
before 26th
September
Register & Pay
before 31st October Standard Price
CONFERENCE + 2
WORKSHOPS £1318.20 +VAT £1438.20 +VAT £1558.20 +VAT £1678.20 +VAT
CONFERENCE + 1
WORKSHOP £1018.80 +VAT £1198.80 +VAT £1258.80 +VAT £1378.80 +VAT
CONFERENCE ONLY £719.40 +VAT £839.40 +VAT £959.40 +VAT £1079.40 +VAT
HALF DAY
WORKSHOP £359.40 +VAT
*VAT is charged at 20%
Tumour Models London
2nd-4th December 2014
Tel: +44 (0)203 141 8700 Email: info@hansonwade.com
tumour-models.com Tumour Models
Venue: This modern and luxurious Kensington
hotel offers a relaxed environment in the heart of
London. Hotels in Kensington with such charm
and supreme comfort are rare. The Millennium
Gloucester Hotel London Kensington effortlessly
combines a convenient location with a unique
sense of style and character.
This hotel is perfectly positioned for visiting many
of the British capital’s greatest attractions. They
include nearby Hyde Park, the Royal Albert Hall,
Kensington Palace, the Natural History Museum
and the Victoria and Albert Museum.
Millennium Gloucester Hotel
London Kensington
4-18 Harrington Gardens
London
SW7 4LH
Accommodation: Overnight
accommodation is not
included in the registration
fee, however accommodation
options will be sent out with
your confirmation email upon
registering.
Tumour-models.com/register
Tel: +44 (0)203 141 8700
Email: register@hansonwade.com
Mail:
Hanson Wade
4th Floor, 52 Grosvenor Gardens,
London, SW1W 0AU
• 10% discount – 3 delegates
• 15% discount – 4 delegates
• 20% discount – 5 or more delegates
Please note that discounts are only valid when
three or more delegates from one company book
and pay at the same time.
TEAM DISCOUNTS*